|

Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy Clinical Trials

1 actively recruiting trial

Also known as: Dapagliflozin

Pipeline

Phase 4: 1

Top Sponsors

  • The University of Hong Kong1

Indications

  • Sodium-GLucose coTransporter-2 Inhibitors1
  • Fontan1
  • Dapagliflozin1
  • Heart Disease1
  • Cardiovascular Diseases1

Other1 trial

The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure
Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.